Definitive Healthcare (US:DH)2026-02-26 23:02Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $61.5 million, down 1% year-over-year, but above the high end of guidance [4][21] - Adjusted EBITDA was $18.1 million, representing a margin of 29%, which was $1.1 million above the high end of guidance [4][21] - Adjusted net income was $8.6 million, resulting in $0.06 of non-GAAP earnings per share [21] - Unlevered Free Cash Flow for the trailing 12 months was approximately $55 million [5][21] - Full year 2025 total revenue was $241.5 million, a 4% decline year-over-year [23] Business Line Data and Key Metrics Changes - Subscription revenues were $58.5 million, down 3% year-over-year, or down 7% excluding data partnership contributions [21] - Professional services revenue increased by 49% year-over-year, driven by traditional analytics engagements and a ramp-up in digital activations [22] - Adjusted gross profit for Q4 was $50.2 million, flat from Q4 2024, with a gross profit margin of 82% [22] Market Data and Key Metrics Changes - Gross dollar retention improved by about 2 points year-over-year, indicating stabilization efforts are taking effect [23][43] - Net dollar retention declined due to ongoing pressure in upsell opportunities [23][45] Company Strategy and Development Direction - The company focuses on four strategic pillars: data differentiation, integrations, customer success, and innovation [5][18] - A new claims data source was introduced, restoring claims data volumes to above historical levels [6][7] - The company aims to return to consistent revenue growth while improving customer retention [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the remediation of claims data disruption and its positive impact on performance moving into 2026 [37][46] - The macro environment remains challenging, but the company is focused on areas it can control and is making necessary investments [20][33] - Management expects modest improvements in net dollar retention in 2026, viewing 2025 as the bottom [56][79] Other Important Information - The company capitalized about $6 million in software development spend, a $5 million increase over the prior year [25] - Deferred revenue at the end of Q4 was $99 million, up 6% year-over-year [25] Q&A Session Summary Question: Update on demand environment across end markets - Management noted improvements in retention trends and confidence in the strategy focused on data quality and integrations [37][39] Question: Insights on renewal cycles and end markets - Management highlighted improvements in gross dollar retention driven by enterprise customers, particularly in life sciences [43][44] Question: Impact of AI on customer conversations - Management emphasized that AI is seen as a competitive advantage, enhancing existing workflows rather than detracting from traditional vendors [52][54] Question: Expectations for net dollar retention recovery - Management expects modest improvements in net dollar retention in 2026, with confidence stemming from product innovation and data remediation efforts [56][79] Question: Dynamics in the life sciences end market - Management reported stabilization in gross dollar retention and ongoing engagement with long-standing relationships in the life sciences space [85][86]